REFERENCES
- Pirmohamed M., James S., Meakin S., Green C., Scott A. K., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 2004; 329: 15–19, [CSA]
- Meyerhardt J. A., Mayer R. J. Systemic therapy for colorectal cancer. N. Eng. J. Med. 2005; 325(5)476–487, [CSA], [CROSSREF]
- Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol. 1998; 16: 3537–3541, [CSA]
- van Kuilenburg A. B.P., Haasjes J., Richel D. J., Zoetekouw L., van Lenthe H., et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 2000; 6: 4705–4712, [CSA]
- Milano G. A., Etienne M. C., Pierrefite V., Barberi-Heyob M., Deporte-Fety R., Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer 1999; 79: 627–630, [CSA], [CROSSREF]
- Johnson M. R., Diasio R. B. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme Regul. 2001; 41: 151–157, [CSA], [CROSSREF]
- van Kuilenburg A. B.P. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 2004; 40: 939–950, [CSA], [CROSSREF]
- Mattison L. K., Ezzeldin H., Carpenter M., Modak A., Johnson M. R., Diasio R. B. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin. Cancer Res. 2004; 10: 2652–2658, [CSA], [CROSSREF]
- van Kuilenburg A. B.P., Meinsma J. R., Zoetekouw L, van Gennip A. H. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+lg > a mutation. Int. J. Cancer 2002; 101: 253–258, [CSA], [CROSSREF]
- van Kuilenburg A. B.P., Van Lenthe H., Tromp A., Veltman P. C.J., van Gennip A. H. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin. Chem. 2000; 46: 9–17, [CSA]
- Gardiner S. J., Begg E J. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?. Pharmacogenet. Genomics 2005; 15(5)365–369, [CSA]
- Volk J., Reinke F., van Kuilenburg A. B.P., van Gennip A. H., Schlichting C., Ganser A., Schöffski P. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann. Oncol. 2001; 72: 569–571, [CSA], [CROSSREF]
- Douillard J.-Y., Hoff P. M., Skillings J. R., Eisenberg P., Davidson N., et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2002; 20: 3605–3616, [CSA], [CROSSREF]
- Carmichael J., Popiela T., Radstone D., Falk S., Borner M., et al. Randomized comparitive study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2002; 20: 3617–3627, [CSA], [CROSSREF]
- Electronic file, Available at: http://www.emea.eu.int/humandocs/ Humans/EPAR/Xeloda/Xeloda.htm. Accessed